London, New York and Tokyo, July 6 2020 - The Sage Group Inc. today announced that Gemseki Japan, led by Hideyuki Hirama, will join its organization as lead partner for Japan and Korea. “We are delighted that Hideyuki and his Gemseki organization has decided to join forces with Sage. Hideyuki and his colleagues will bring his wide-ranging expertise with healthcare and bioscience clients in Japan to The Sage Group. Hideyuki has a prestigious career in the pharma industry in his previous role at Board level with Shin Nippon Biomedical Laboratories.” said Dr. Bill Mason, Executive Director of The Sage Group. “Gemseki’s experienced team will work with Sage’s clients in North America and Japan to provide access to major corporate pharma and medtech entities in Japan and Korea.”
Hideyuki Hirama has a Bachelor’s Degree in Law and an MBA from Harvard University. He was for six years a Board Member and head of strategy and planning for Shin Nippon Biomedical Laboratories (SNBL Japan), which was founded in Kagoshima as Japan’s first contract research organization in 1957. SNBL today is one of Japan’s largest CRO organisations. Hideyuki has engaged in numerous licensing and partnering programs for Japanese companies. He is based in Tokyo where his company Gemseki leads corporate finance activities for Japanese healthcare and life science companies, and he is President and CEO.
The June 2020 issue of Industry Era, a U.S. technology magazine, featured Gemseki President and CEO, Hideyuki Hirama, as one of the “10 most inspiring CEOs to watch in 2020.” The article discusses how Gemseki is facilitating open innovation though its online ‘Drug Candidate Marketplace’, where drug candidates are listed and available for partnering. Mr. Hirama stated, “We strive to make contributions to humanity and society by supporting the best development of valuable d